363 related articles for article (PubMed ID: 32505588)
1. Treatment of pulmonary disease caused by Mycobacterium kansasii.
Huang HL; Lu PL; Lee CH; Chong IW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
7. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
Park HK; Koh WJ; Shim TS; Kwon OJ
Yonsei Med J; 2010 Jul; 51(4):552-6. PubMed ID: 20499421
[TBL] [Abstract][Full Text] [Related]
9. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
11. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil.
de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP
J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506
[TBL] [Abstract][Full Text] [Related]
12. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
13. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain].
Leal Arranz MV; Gaafar A; Unzaga Barañano MJ; Crespo Notario JA; Cisterna Cáncer R; García Cebrián F
Arch Bronconeumol; 2005 Apr; 41(4):189-96. PubMed ID: 15826528
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
17. Mycobacterium kansasii.
Johnston JC; Chiang L; Elwood K
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
[TBL] [Abstract][Full Text] [Related]
18. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London.
Davies BS; Roberts CH; Kaul S; Klein JL; Milburn HJ
Scand J Infect Dis; 2012 Nov; 44(11):815-9. PubMed ID: 23078529
[TBL] [Abstract][Full Text] [Related]
19. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
[TBL] [Abstract][Full Text] [Related]
20. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
